Author Archives: Bruno Quinney

#AI / data analytics / healthtech / informatics #Genomics #Multi-omics

Tipping the genomic scales: Preparing for the integrated multiomics era

This paid-for advertorial by Sampled appeared in DDW Volume 27 – Issue 2, Spring 2026   How sequencing innovation and integrated workflows are enabling reproducible multiomic studies. Genomics has always played a central role in advancing research and drug discovery, but utilising genomic data to inform decisions in the clinic has not always been possible. Progress in this area has been limited… Read More

#Exclusive Content

Cytokine release syndrome
#Clinical Trial Authorisation #Cytokine Release Syndrome (CRS) #MHRA #Poolbeg Pharma

MHRA grants trial authorisation to CRS therapy 

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Clinical Trial Authorisation to a potential preventative therapy for Cytokine Release Syndrome (CRS).  The TOPICAL trial will investigate Poolbeg Pharma’s therapy, POLB 001, in approximately 30 relapsed/refractory multiple myeloma patients receiving the approved bispecific antibody teclistamab.  Previous research showed POLB 001, if approved,… Read More

#News #Regulatory

Proteomics
#Biotech #Oncology #Precision medicine #Proteomics

Nomic and Broad Clinical Labs to build proteomics platform 

Biotechnology company Nomic Bio has announced a partnership with Broad Clinical Labs (BCL) to build a scalable proteomics platform.  The organisations will look to integrate Nomic’s Omni 1000 solution into BCL’s existing capabilities to develop new application-specific solutions.   Based on nELISA technology, Nomic says Omni 1000 measures… Read More

#News

#Clinical trial #Huntington's disease #Regulatory #uniQure

From the Editor: Terms and Conditions

The recent report that pharmaceutical company uniQure’s data from its Phase I/II studies provide insufficient evidence for the approval of its investigational gene therapy drug for Huntington’s disease (HD) are a major blow for patients.  Huntington’s disease is a rare genetic disorder that can affect around 5-10 people per 100,000, and which is… Read More

#Exclusive Content #Opinion

#Idiopathic pulmonary fibrosis #Lung disease #Respiratory

Digital lung ‘twins’ could predict drug efficacy in humans 

Digital lung ‘twins’ could help predict the efficacy of inhaled drugs in patients with respiratory problems.  Healthcare company Ebenbuild has developed lung digital twin technology, which uses patient-specific models to predict drug deposition.  According to a study published in Nature Communications Medicine, the validated technology… Read More

#News

#Arthritis #Cancer research #Immune response #NHS #Oncology #Ovarian cancer #SynaptixBio #Tumour biology #UK government #University of Birmingham

DDW Highlights: 21 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, key breakthroughs emerged in cancer research. Elsewhere, regulatory reforms have accelerated clinical… Read More

#Podcasts

#India #R&D #Women in STEM

India’s first women-led chemistry synthesis lab opened 

A chemistry synthesis laboratory entirely operated and led by women scientists has opened in India.  ChemiSHE, launched by CRDMO Aragen, was inaugurated on 8 April at Aragen’s Mallapur campus in Hyderabad.  Aragen says ChemiSHE is part of a broader strategic initiative to strengthen gender diversity across the company’s scientific workforce and create structured… Read More

#News

CAR-T cell therapy
#CAR T-cell therapy #Circio Holding

Circio and Acuitas partner on CAR-T cell therapy technology 

Biotechnology companies Circio Holding and Acuitas Therapeutics have entered a technology evaluation agreement for an in vivo CAR-T cell therapy.  As part of the agreement, Circio’s circVec circular RNA expression technology will be tested alongside Acuitas’ proprietary T-cell-targeted lipid nanoparticle (LNP) delivery system. The companies aim to assess whether Acuitas’ LNP technology can be deployed to deliver circVec for novel in vivo CAR-T therapy with superior… Read More

#Business & Investment #News

#Clinical trial #Freya Biosciences #Women's health

Freya Biosciences reports positive data on IVF therapeutic 

Immunology company Freya Biosciences has reported positive Phase I results for its treatment for IVF-related embryo implantation failure.  FB301, a defined multi-strain Lactobacillus consortium developed using Freya’s Dyscover platform, was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints met.  The trial was a… Read More

#News

Soft tissue sarcoma
#Investment #Sarcoma #Storm Therapeutics

STORM secures $56m financing for sarcoma treatment 

Biotechnology company STORM Therapeutics has announced it has secured $56 million in a Series C financing to support its sarcoma treatment.  The proceeds will support the advancement of STC-15, a first‑in‑class, oral small-molecule inhibitor of METTL3. This extends to funding the company’s Phase II monotherapy study in selected sarcoma indications, in which the… Read More

#Business & Investment #News

#Arthritis #Cancer research #Immune response #NHS #Oncology #Ovarian cancer #SynaptixBio #Tumour biology #UK government #University of Birmingham

This week in Drug Discovery (13 – 17 April) 

News round-up for 13 – 17 April by Bruno Quinney, Content Team at DDW.  This week, breakthroughs have emerged in cancer research. Elsewhere, regulatory reforms have accelerated clinical trial set up in the UK.  The top stories:    Novel therapy could slow tumour growth… Read More

#News

Science connection and networking
#BioTrinity #Life sciences

OBN rebrands as BioUK to capitalise on life sciences success 

OBN has rebranded to BioUK to reflect its goal of catalysing on success in the UK life sciences sector.  The not-for-profit organisation says the updated brand identity has been developed to align with its position following a period of sustained growth, providing support throughout the UK to help R&D… Read More

#News

ulcerative colitis
#Biotech #Clinical trial #Ulcerative colitis (UC)

Spyre Therapeutics reports positive data for UC treatment 

Biotechnology company Spyre Therapeutics has reported positive results for its treatment for moderate-to-severely-active ulcerative colitis (UC).  SPY001, a potential best-in-class anti-α4β7, met its primary endpoint in a Phase II trial, with a significant reduction of 9.2 points from baseline at Week 12 in Robart’s Histopathology Index (RHI) score. Read More

#News

#Antibody drug conjugate (ADC) #VALANX Biotech

VALANX sets up SAB to advance ADC therapeutics 

Biotech company VALANX has unveiled its new Scientific Advisory Board as it prepares to advance antibody-drug conjugate (ADC) therapeutics.  John Lambert has been appointed as Chair, with Morris Rosenberg and Peter de Waele serving on the board alongside him.  Lambert is a leading expert in ADC discovery… Read More

#News

Digital pathology
#Dermatology #R&D #Supercomputing

Supercomputing collaboration to advance dermatology research 

Research and development in medical dermatology is set to be advanced by supercomputing and artificial intelligence.  Biopharmaceutical company Almirall has announced an expanded collaboration with the Barcelona Supercomputing Center (BSC), aiming to address the needs of patients with skin conditions.  The partnership builds on previous successful R&D joint… Read More

#News

#Asgard Therapeutics #Biotech

Asgard Therapeutics appoints Dr Wolfram Brugger as CMO 

Biotechnology company Asgard Therapeutics has appointed Dr Wolfram Brugger as Chief Medical Officer.  Brugger, who has been involved in more than 130 Phase I to III clinical oncology trials across a wide variety of cancer types, has been appointed to strengthen Asgard’s leadership as it prepares to transition… Read More

#News